Thanks for the CC summary bontz and yes it would have been great to get the last question answered. I can’t understand why MSB would not be planning a RCT trial in adults now, to avoid the RCT argument being used again. SI indicated RCT would not be necessary as the patients would have not responded to existing treatments and have no other option, but how does that differ to the child study?
Thanks for the CC summary bontz and yes it would have been great...
-
- There are more pages in this discussion • 768 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $18.15M | 12.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3418 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 24361 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |